Π electron-stabilized polymeric micelles potentiate docetaxel therapy in advanced-stage gastrointestinal cancer

Liang, Chenghua; Bai, Xiaojing; Qi, Cuiling; Sun, Qingxue; Han, Xiaoyan; Lan, Tianyun; Zhang, Haibo; Zheng, Xiaoming; Liang, Rongpu; Jiao, Ju; Zheng, Zongheng; Fang, Jiafeng; Lei, Purun; Wang, Yan; Möckel, Diana; Metselaar, Josbert M.; Storm, Gert; Hennink, Wim E.; Kießling, Fabian; H, Wei; Lammers, Twan; Shi, Yang; Wei, Bo

doi:10.1016/j.biomaterials.2020.120432

Cited by 34 publications

(22 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[76] More recently, a PEGylated micellar formulation containing docetaxel was shown to achieve an impressive in vivo tumor regression, in multiple gastrointestinal cancer models. [77] Polymer-based NPs have also been extensively explored as carriers of cytotoxic drugs. Couvreur et al pioneered the development of polycyanoacrylate NPs loaded with cytotoxic drugs.…”

Section: Relevant Nanocarriers For the Delivery Of Cytotoxic Drugsmentioning

confidence: 99%

Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues

Dacoba

Anthiya

Berrecoso

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

Research efforts towards cancer therapeutics have resulted in the development of a variety of pharmacological molecules, including small synthetic molecules and biological drugs (RNA-based therapies and monoclonal antibodies-mAbs), intended to target tumor or immune-related cells, or their signaling mediators. The majority of them present important biopharmaceutical problems related to their difficulties for overcoming biological barriers and reach their targets. Nanotechnology has been, for more than 60 years, trying to solve these problems. As knowledge in drug discovery, molecular biology, and biomaterials advances, there has been significant progress in the adequate design of nanodelivery strategies that may significantly contribute to the exploitation of the new therapies. This review provides a critical overview of the current potential of nanotechnology to solve problems associated with the different categories of drugs. Starting with the general concept of passive and active targeting, it presents the distinct advantages that delivery technologies have shown to date for improving the therapeutic outcome of small drugs with cytotoxic activity, RNA-and mAb-based therapies. Moreover, it precisely describes the benefits of combining immunotherapies and nanotechnology. The most advanced technologies are put into perspective in relation to their translational pathway and the future avenues for nano-oncologicals.

show abstract

Section: Relevant Nanocarriers For the Delivery Of Cytotoxic Drugsmentioning

confidence: 99%

Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues

Dacoba

Anthiya

Berrecoso

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…A variety of natural or synthetic nanomaterials have been developed for biomedical application including DNA nanostructures [ 7 ], polymeric micelles [ 8 ], silica nanoparticles [ 9 ], gold nanoparticles or carbon nanotubes [ 10 , 11 ]. They are commonly used to develop favorable formulations for different therapeutic agents, particularly insoluble compounds or biotherapeutics [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Aptamer-Enabled Nanomaterials for Therapeutics, Drug Targeting and Imaging

Liu

Wang

et al. 2022

Cells

View full text Add to dashboard Cite

A wide variety of nanomaterials have emerged in recent years with advantageous properties for a plethora of therapeutic and diagnostic applications. Such applications include drug delivery, imaging, anti-cancer therapy and radiotherapy. There is a critical need for further components which can facilitate therapeutic targeting, augment their physicochemical properties, or broaden their theranostic applications. Aptamers are single-stranded nucleic acids which have been selected or evolved to bind specifically to molecules, surfaces, or cells. Aptamers can also act as direct biologic therapeutics, or in imaging and diagnostics. There is a rich field of discovery at the interdisciplinary interface between nanomaterials and aptamer science that has significant potential across biomedicine. Herein, we review recent progress in aptamer-enabled materials and discuss pending challenges for their future biomedical application.

show abstract

“…[5][6][7][8] Stabilization by non-covalent interaction, e.g., by p-p-stacking seems promising and simple yet is barely understood in its full depth for drug delivery systems with triggered release profiles. [9][10][11][12][13] Crosslinking by dynamic covalent bonds is thus a straightforward approach accounting for drug release by either disease-related or external stimuli. 5 Free radical cross-linking of thermosensitive poly(ethylene glycol)-b-poly(N-(2-hydroxypropyl)methacrylamide)based copolymers has been combined with a pH-sensitive docetaxel-pro drug cross-linker (CPC634) and is currently under clinical investigation in phase II studies for the treatment of ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%